Related Experiment Videos
[Therapy of testicular germ cell tumors. Current status of the MAHO studies]
Abstract:
The GPOH-MAHO trials designed in 3/82 and 7/88 for treatment of childhood testicular germ cell tumors registered 3/92 105 pts. In MAHO 82 study 57 pts. and in MAHO 88 study 48 pts. were treated. Histologically 60% of the tumors revealed yolk sac tumors (YST), 22% teratomas (TD) and 18% malignant teratomas (MTI, MTU, MTT). Beside unilateral orchiectomy, according to stage and histology a stratified chemotherapy was administered. Standard chemotherapy consisted of 4 courses VLB, BLM, DDP, after 2 courses standard chemotherapy if vital tumor was suspected: explorative laparatomy. According to laparatomy some patients received salvage chemotherapy of 3 courses VP 16, IFO and DDP. The following results were obtained: YST: 59 pts. with stage I. Of these 10 received adjuvant chemotherapy with VLB, BML, DDP. 49 pts. were followed according to wait and see policy and not treated by adjuvant chemotherapy; 8 pts. had a relapse. 5 were treated with standard chemotherapy and 1 pt. with salvage therapy. 1 pt. had stage II and another stage III. Both received standard chemotherapy. The survival of all 61 pts. is 100%. Median observation time is 4 years. TD: 25 pts. had stage I. No chemotherapy was given. The relapse free survival is 100%. Median observation time is 4 years. Malignant teratomas (MTI, MTU, MTT): 8 pts. had stage I. Of these 3 received adjuvant chemotherapy, 5 lymphadenectomy without chemotherapy. All patients survived without relapse. 8 pts. had stage II and received standard chemotherapy, of these 4 pts. had stage IIc and explorative laparotomy was done. According to the result 2 pts. received salvage therapy. All pts. survived relapse free.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Childhood testicular germ cell tumors (GCTs) treated with stratified chemotherapy showed excellent survival rates. Yolk sac tumors and teratomas had 100% survival, with tailored chemotherapy and observation strategies proving effective.
Area of Science:
- Pediatric Oncology
- Medical Research
- Clinical Trials
Context:
- The GPOH-MAHO trials investigated childhood testicular germ cell tumors (GCTs) starting in 1982 and 1988.
- A total of 105 patients were registered, with 60% diagnosed with yolk sac tumors (YST), 22% with teratomas (TD), and 18% with malignant teratomas (MTI, MTU, MTT).
Purpose:
- To evaluate the efficacy of stratified chemotherapy regimens in treating pediatric GCTs.
- To assess survival and relapse rates based on tumor histology and stage.
Summary:
- Standard chemotherapy involved 4 courses of Vinblastine (VLB), Bleomycin (BLM), and Cisplatin (DDP). Explorative laparotomy was performed if vital tumor was suspected after two courses.
- Patients with YST (Stage I) had varying treatments: 10 received adjuvant chemotherapy, while 49 were observed; 8 relapsed and were treated. All 61 YST patients survived.
- Teratomas (Stage I) had 100% relapse-free survival without chemotherapy. Malignant teratomas (Stage I) showed no relapses with or without adjuvant therapy; Stage II malignant teratomas treated with chemotherapy also had no relapses.
Impact:
- The study demonstrates high survival rates for childhood GCTs, highlighting the effectiveness of tailored treatment protocols.
- Observation (
- wait and see
- ) policies for low-stage YST and TD are validated, alongside the success of salvage chemotherapy for relapsed cases.